Waiving vaccine IP doesn't affect market assessment: Morningstar
Stocks
Waiving vaccine IP doesn't affect market assessment: Morningstar
We are not changing our fair values to COVID-19 vaccine firms following the proposed waiver on intellectual property protection.
Vaccine rollout and herd immunity to end the pandemic
Stocks
Vaccine rollout and herd immunity to end the pandemic
Covid will create a $52bn vaccine and treatment market and usher in immunity by 2023, writes Morningstar's Karen Andersen.
What next in the hunt for a covid-19 vaccine?
Markets
What next in the hunt for a covid-19 vaccine?
Resurgences in outbreaks make it clear that ending the pandemic requires more than testing, contact tracing, and social distancing, says...
Three vaccines capable of US authorisation in 2020
Stocks
Three vaccines capable of US authorisation in 2020
We expect most US adults will be vaccinated in the first half of 2021, writes Morningstar healthcare strategist Karen Andersen.
What a Covid-19 vaccine means for investors
Markets
What a Covid-19 vaccine means for investors
Three new vaccines for coronavirus look poised for emergency use authorisation in the US this autumn. What does that mean for investors?
Coronavirus vaccine progress accelerates
Markets
Coronavirus vaccine progress accelerates
Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.
What to expect as the virus continues
Stocks
What to expect as the virus continues
Christine Benz and Karen Andersen discuss Morningstar's latest views on stopping the spread of the virus as well as the economic implications.
Morningstar cuts GDP forecasts but tips V-shaped recovery
Markets
Morningstar cuts GDP forecasts but tips V-shaped recovery
A COVID-19 recession doesn't fit the mould of a 2008-style recession with longer-lasting economic impact.
Path to a vaccine emerges as investors overreact
Markets
Path to a vaccine emerges as investors overreact
The US is slowing the coronavirus spread as drug makers race toward a vaccine; while the longer-term economic effect will be modest, say Morningstar...
Coronavirus market selloff 'a gross overreaction'
Markets
Coronavirus market selloff 'a gross overreaction'
Morningstar weighs supply and demand factors in assessing COVID-19's long-term effect on global GDP as minimal.
of 2
Viewing 1 to 10 of 14